Table 1 Patient characteristics
From: Diagnostic value of 18F-FDG PET/MRI for staging in patients with endometrial cancer
Patient | Age | Histology | Pathological stage | PET/MRI stage | ceMRI & ceCT stage |
|---|---|---|---|---|---|
1 | 75 | serous | T3bN2M0 | T3bN2M0 | T3bN1M0 |
2 | 53 | G3 | T1bN0M0 | T1bN0M0 | T1bN0M0 |
3 | 68 | G1 | T1aNXM0 | T1aNXM0 | T1aNXM0 |
4 | 68 | serous | T3aNXM1 | T3aNXM1 | T3aNXM1 |
5 | 51 | G3 | T2N1M0 | T2N1M0 | T2N0M0 |
6 | 70 | serous | T1aN0M0 | T1aN0M0 | T1aN0M0 |
7 | 69 | G1 | T1aN0M0 | T1bN0M0 | T1bN0M0 |
8 | 38 | AH | AH | T1bNXM0 | T1bNXM0 |
9 | 66 | CS | T1aN0M0 | T1aN0M0 | T1aN0M0 |
10 | 47 | G1 | T3aNXM0 | T3aNXM0 | T3aNXM1 |
11 | 58 | G2 | T1aN0M0 | T1aN0M0 | T1aN0M0 |
12 | 67 | G1 | T1bN0M0 | T1bN0M0 | T1bN0M0 |
13 | 68 | serous | T3bN0M1 | T1aN0M0 | T1bN0M0 |
14 | 85 | G2 | T1bNXM0 | T1aNXM0 | T1aNXM0 |
15 | 41 | G1 | T1aNXM0 | T1aNXM0 | T1aNXM0 |
16 | 61 | serous | T1bN0M0 | T1bN0M0 | T1bN0M0 |
17 | 65 | G1 | T2N0M0 | T2N0M0 | T2N0M0 |
18 | 42 | AH | AH | AH | AH |
19 | 49 | G1 | T2N0M0 | T2N0M0 | T2N0M0 |
20 | 42 | G1 | T1aN0M0 | T1aN0M0 | T1aN0M0 |
21 | 50 | G2 | T2N0M0 | T1aN0M0 | T1aN0M0 |
22 | 83 | serous | T3bNXM1 | T2NXM0 | T1bNXM1 |
23 | 58 | G1 | T1aNXMX1 | T1aNXMX1 | T1aNXMX |
24 | 75 | G1 | T1aN0M0 | T1aN0M0 | T1aN0M0 |
25 | 76 | G1 | T1aN0M0 | T1aN0M0 | T1aN0M0 |
26 | 54 | G1 | T1aN0M0 | T1aN0M0 | T1aN0M0 |
27 | 62 | G1 | T1aN0M0 | T1aN0M0 | T2N0M0 |
28 | 59 | G1 | T1aN0M0 | T1aN0M0 | T1aN0M0 |
29 | 50 | G1 | T1aNXM0 | T1aNXM0 | T1aNXM0 |
30 | 58 | G1 | T1aN0M0 | T1bN0M0 | T2N0M0 |
31 | 86 | G3 | T1bN0M0 | T1bN1M0 | T1bN0M0 |
32 | 51 | G1 | T1aNXM0 | T1aNXM0 | T1aNXM0 |
33 | 74 | CS | T3aNXM0 | T2NXM0 | T2NXM0 |
34 | 68 | G2 | T1bN0M0 | T1bN0M0 | T1bN0M0 |
35 | 63 | G2 | T1bN0M0 | T1bN1M0 | T1bN1M0 |
36 | 54 | G1 | T1aNXM0 | T1aNXM0 | T1aNXM0 |